Is R-CHOP Therapy a Lymphoma Growth Factor? - Aix-Marseille Université Access content directly
Journal Articles American Journal of Therapeutics Year : 2016

Is R-CHOP Therapy a Lymphoma Growth Factor?


This article describes the first reported case of dramatic lymphocytosis flare after initiation of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy for an indolent lymphoma. The study patient exhibited a marginal zone lymphoma with mild nodal involvement but packed infiltration of the bone marrow. After initiation of RCHOP therapy, lymphocyte count increased from 329 to 707 x 10(9)/L at day 7. Patient exhibited grade III infusion-related side effect during rituximab therapy. Lymphocyte flare was not accompanied with other clinical manifestation such as lymph node enlargement. Because patient's bone marrow aspirate showed a packed infiltration, it was hypothesized that lymphocytosis flare was a link to lymphocyte release from bone marrow and lymphocyte demargination. This report highlights the necessity to be vigilant after initiation of RCHOP therapy for lymphoma when pathologist notified a pack infiltration of the bone marrow.
No file

Dates and versions

hal-01460124 , version 1 (07-02-2017)



Laure Farnault, Cédric Mercier, Yael Berda-Haddad, Gérard Sébahoun, Régis Costello. Is R-CHOP Therapy a Lymphoma Growth Factor?. American Journal of Therapeutics, 2016, 23 (1), pp.E295-E297. ⟨10.1097/01.mjt.0000434041.54749.3d⟩. ⟨hal-01460124⟩


22 View
0 Download



Gmail Facebook X LinkedIn More